CliffBio
biologic

Gammagard, Gammagard S/D, Iveegam

Immune Globulin Intravenous (Human)

Loss of exclusivityJuly 2012projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameGammagard, Gammagard S/D, Iveegam
Active ingredientImmune Globulin Intravenous (Human)
Strength10G
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2000
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gammagard, Gammagard S/D, Iveegam patent cliff — loss of exclusivity July 2012 | CliffBio